BEAM241018C30000
- 0.20
- -0.10-33.33%
Beam Therapeutics Newsroom
Beam Therapeutics Price Target Maintained With a $27.00/Share by RBC Capital
RBC Capital Maintains Beam Therapeutics(BEAM.US) With Hold Rating, Maintains Target Price $27
RBC Capital Sticks to Its Hold Rating for Beam Therapeutics (BEAM)
JonesTrading Initiates Beam Therapeutics(BEAM.US) With Hold Rating
Stifel Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Raises Target Price to $69
Stifel Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Cuts Target Price to $69
Beam Therapeutics Is Maintained at Buy by Stifel
Beam Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80
Analysts Are Bullish on Top Healthcare Stocks: Beam Therapeutics (BEAM), Taysha Gene Therapies (TSHA)
Beam Therapeutics: Hold Rating With Stable Financial Outlook Amid Clinical Pipeline Progress and Upcoming Data Releases
Beam Therapeutics Price Target Cut to $31.00/Share From $33.00 by Barclays
Beam Therapeutics Analyst Ratings
RBC Capital Reiterates Sector Perform on Beam Therapeutics, Maintains $27 Price Target
Analysts Conflicted on These Healthcare Names: Nyxoah (NYXH), MultiPlan (MPLN) and Beam Therapeutics (BEAM)
Barclays Keeps Their Hold Rating on Beam Therapeutics (BEAM)
Beam Therapeutics' Advancements Bolster Buy Rating: Momentum in Gene Editing Trials and Regulatory Progress
HC Wainwright & Co. Initiates Coverage On Beam Therapeutics With Buy Rating, Announces Price Target of $80
Beam Therapeutics Analyst Ratings